Docket #: S25-582
A New Approach to the Persistent Public Health Challenge of Opioid Overdose
Drug addiction remains one of the most significant preventable public health crises in the United States. Researchers at Stanford have designed a combination therapeutic intended to address this critical unmet healthcare need. The treatment landscape is crowded and growing, yet current standard-of-care options still leave a gap in outcomes.
Early preclinical evaluation in mice to address the efficacy, tolerability, and durability of protection has produced encouraging results. Further studies, manufacturing development, and regulatory work will be needed to support clinical evaluation.
Building on proprietary Stanford technology, the approach takes a different path to a long-standing problem. The goal is to deliver meaningful public health impact across community and institutional care settings.
Stage of Development
Preclinical (in vivo proof-of-concept)
Applications
- Institutional and community care settings
Advantages
- Addresses a limitation that current standard-of-care therapeutics were not designed to solve
- Offers ease of administration
Patent Status
Provisional patent application filed
Related Links
Similar Technologies
-
Monoclonal Antibody to Human CD81, 5A6 S97-184Monoclonal Antibody to Human CD81, 5A6
-
Animal Model of Social Dysfunction S10-332Animal Model of Social Dysfunction
-
Biomarker to Enrich for Inflammation-Resistant Cartilage to Treat Osteoarthritis S16-017Biomarker to Enrich for Inflammation-Resistant Cartilage to Treat Osteoarthritis